MedTrace Logo

A Research for Combination of Prostate Health Index (Phi) and mpMRI PI-RADS in the Diagnosis of Prostate Cancer

NCT05179707 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 936

Last updated 2022-10-12

No results posted yet for this study

Summary

Before prostate puncture, the patient's serum was collected for PHI detection, and multi-parameter MRI was performed to obtain the PI-RADS score. The sensitivity and specificity of PHI combined with PI-RADS score in the diagnosis of clinically significant prostate cancer were explored.

Conditions

Sponsors & Collaborators

  • Zibo Central Hospital

    collaborator OTHER_GOV

  • Qilu Hospital of Shandong University

    lead OTHER

Eligibility

Min Age
50 Years
Max Age
80 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-02-01
Primary Completion
2023-10-01
Completion
2023-10-01

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05179707 on ClinicalTrials.gov